Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The papanicolaou society of cytopathology guidelines for pancreatobiliary cytology

Diagnostic Cytopathology

Volumn 42, Issue 4, 2014, Pages 351-362

  Layfield, Lester J ^a   Ehya, Hormoz ^b   Filie, Armando C ^c   Hruban, Ralph H ^d   Jhala, Nirag ^e   Joseph, Loren ^f   Vielh, Philippe ^g   Pitman, Martha B ^h  

^a University of Missouri   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ancillary studies; biliary tract; EUS; fine needle aspiration; molecular diagnosis; pancreas

Indexed keywords

AMYLASE; BETA CATENIN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GASTRIN; GLUCAGON; INSULIN; K RAS PROTEIN; MESOTHELIN; MICRORNA; PROTEIN P16; PROTEIN P53; RING FINGER PROTEIN 43; SMAD4 PROTEIN; SOMATOSTATIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ACINAR CELL CARCINOMA; ARTICLE; BILIARY TRACT DISEASE; BLASTOMA; CHOLESTASIS; CYTODIAGNOSIS; DNA DETERMINATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; PANCREAS ADENOCARCINOMA; PANCREAS CYST; PANCREAS DISEASE; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATOBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ANCILLARY STUDIES; BILIARY TRACT; EUS; FINE-NEEDLE ASPIRATION; MOLECULAR DIAGNOSIS; PANCREAS;

BILE DUCT NEOPLASMS; BILE DUCTS; CONSTRICTION, PATHOLOGIC; CYTODIAGNOSIS; HUMANS; PANCREAS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; SOCIETIES, MEDICAL;

EID: 84896341742     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23093     Document Type: Article

References (124)

1. Mahmoudi N, Enns R, Amar J, AlAli J, Lam E, Telford J,. Biliary brush cytology: Factors associated with positive yields on biliary brush cytology. World J Gastroenterol 2008; 14: 569-573.
2. Weber A, von Weyhern C, Fend F, et al. Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma. World J Gastroenterol 2008; 14: 1097-1101.
3. Fritcher EG, Kipp BR, Halling KC, et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 2009; 136: 2180-2186.
4. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004; 99: 1675-1681.
5. Kocjan G, Smith AN,. Bile duct brushings cytology: Potential pitfalls in diagnosis. Diagn Cytopathol 1997; 16: 358-363.
6. Layfield LJ, Wax TD, Lee JG, Cotton PB,. Accuracy and morphologic aspects of pancreatic and biliary duct brushings. Acta Cytol 1995; 39: 11-18.
7. Logrono R, Kurtycz DF, Molina CP, Trivedi VA, Wong JY, Block KP,. Analysis of false-negative diagnoses on endoscopic brush cytology of biliary and pancreatic duct strictures: The experience at 2 university hospitals. Arch Pathol Lab Med 2000; 124: 387-392.
8. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131: 1064-1072.
9. Ponchon T, Gagnon P, Berger F, et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: Results of a prospective study. Gastrointest Endosc 1995; 42: 565-572.
10. Volmar KE, Vollmer RT, Routbort MJ, Creager AJ,. Pancreatic and bile duct brushing cytology in 1000 cases: Review of findings and comparison of preparation methods. Cancer 2006; 108: 231-238.
11. Rupp M, Hawthorne CM, Ehya H,. Brushing cytology in biliary tract obstruction. Acta Cytol 1990; 34: 221-226.
12. Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008; 103: 1263-1273.
13. Fritcher EG, Kipp BR, Halling KC, et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 2009; 136: 2180-2186.
14. Kubiliun N, Ribeiro A, Fan YS, et al. EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. Gastrointest Endosc 2011; 74: 541-547.
15. Lee JG, Leung JW, Baillie J, Layfield LJ, Cotton PB,. Benign, dysplastic, or malignant - making sense of endoscopic bile duct brush cytology: Results in 149 consecutive patients. Am J Gastroenterol 1995; 90: 722-726.
16. Lapkus O, Gologan O, Liu Y, et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod Pathol 2006; 19: 907-913.
17. Sebo TJ,. Digital image analysis. Mayo Clin Proc 1995; 70: 81-82.
18. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004; 2: 214-219.
19. Rumalla A, Baron TH, Leontovich O, et al. Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis. Gastrointest Endosc 2001; 53: 500-504.
20. Bacus JW, Grace LJ,. Optical microscope system for standardized cell measurements and analyses. Appl Opt 1987; 26: 3280-3293.
21. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131: 1064-1072.
22. Tretiakova M, Antic T, Westerhoff M, et al. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions. Am J Surg Pathol 2012; 36: 101-108.
23. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL,. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol 2010; 41: 1210-1219.
24. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol 2006; 126: 572-579.
25. Reicher S, Boyar FZ, Albitar M, et al. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses. Pancreas 2011; 40: 1057-1062.
26. Sturm PD, Rauws EA, Hruban RH, et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res 1999; 5: 629-635.
27. Sturm PD, Hruban RH, Ramsoekh TB, et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998; 186: 247-253.
28. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE,. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-3573.
29. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996; 110: 227-231.
30. Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-956.
31. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS,. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 1998; 7: 515-521.
32. Hruban RH, Wilentz RE, Kern SE,. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156: 1821-1825.
33. Hruban RH, Goggins M, Parsons J, Kern SE,. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-2972.
34. Chadwick B, Willmore-Payne C, Tripp S, Layfield LJ, Hirschowitz S, Holden J,. Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas. Appl Immunohistochem Mol Morphol 2009; 17: 31-39.
35. Berthélemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L,. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123: 188-191.
36. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-2474.
37. Wilentz RE, Chung CH, Sturm PD, et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998; 82: 96-103.
38. Maluf-Filho F, Kumar A, Gerhardt R, et al. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. J Clin Gastroenterol 2007; 41: 906-910.
39. Khalid A, McGrath KM, Wilson M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005; 3: 967-973.
40. Hosoda W, Takagi T, Mizuno N, et al. Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol Int 2010; 60: 358-364.
41. Kipp BR, Fritcher EG, Clayton AC, et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn 2010; 12: 780-786.
42. Boldorini R, Paganotti A, Sartori M, et al. Fluorescence in situ hybridisation in the cytological diagnosis of pancreatobiliary tumours. Pathology 2011; 43: 335-339.
43. Barr Fritcher EG, Caudill JL, Blue JE, et al. Identification of malignant cytologic criteria in pancreatobiliary brushings with corresponding positive fluorescence in situ hybridization results. Am J Clin Pathol 2011; 136: 442-449.
44. Huddleston BJ, Lamb RD, Gopez EV, Adler DG, Collins BT,. Cholangiocarcinoma in a 17-year-old boy with primary sclerosing cholangitis and UroVysion™ fluorescent in situ hybridization. Diagn Cytopathol 2012; 40: 337-341.
45. Hart J, Parab M, Mandich D, Cartun RW, Ligato S,. IMP3 immunocytochemical staining increases sensitivity in the routine cytologic evaluation of biliary brush specimens. Diagn Cytopathol 2012; 40: 321-326.
46. Zhan XB, Wang B, Liu F, Ye XF, Jin ZD, Li ZS,. Cyst fluid carcinoembryonic antigen concentration and cytology by endosonography-guided fine needle aspiration in predicting malignant pancreatic mucinous cystic neoplasms. J Dig Dis 2013; 14: 191-195.
47. Leung KK, Ross WA, Evans D, et al. Pancreatic cystic neoplasm: The role of cyst morphology, cyst fluid analysis, and expectant management. Ann Surg Oncol 2009; 16: 281-282.
48. Pitman MB,. In: Cytology of the pancreas, in diagnostic cytopathology., Gray W, Kocjan G, editors. London: Churchill Livingstone: 2010.
49. Yoon WJ, Daglilar ES, Pitman MB, Brugge WR,. Cystic pancreatic neuroendocrine tumors: Endoscopic ultrasound and fine-needle aspiration characteristics. Endoscopy 2013; 45: 189-194.
50. Van der Waaij LA, Van Dulleman HM, Porte RJ,. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: A pooled analysis. Gastrointest Endosc 2005; 62: 383-389.
51. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: A report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126: 1330-1336
52. Lewandrowski KB, Southern JF, Pins MR, Compton CC, Warshaw AL,. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. Ann Surg 1993; 217: 41-47.
53. Sperti C, Pasquali C, Guolo P, Polverosi R, Liessi G, Pedrazzoli S,. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Cancer 1996; 78: 237-243.
54. Sperti C, Pasquali C, Perasole A, Liessi G, Pedrazzoli S,. Macrocystic serous cystadenoma of the pancreas: Clinicopathologic features in seven cases. Int J Pancreatol 2000; 28 (1-7.
55. Räty S, Sand J, Alfthan H, Haglund C, Nordback I,. Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions. J Gastrointest Surg 2004; 8: 569-574.
56. Weissmann D, Lewandrowski K, Godine J, Centeno B, Warshaw A,. Pancreatic cystic islet-cell tumors. Clinical and pathologic features in two cases with cyst fluid analysis. Int J Pancreatol 1994; 15: 75-79.
57. Pins MR, Compton CC, Southern JF, Rattner DW, Lewandrowski KB,. Ciliated enteric duplication cyst presenting as a pancreatic cystic neoplasm: Report of a case with cyst fluid analysis. Clin Chem 1992; 38: 1501-1503.
58. Centeno BA, Stockwell JW, Lewandrowski KB,. Cyst fluid cytology and chemical features in a case of lymphoepithelial cyst of the pancreas: A rare and difficult preoperative diagnosis. Diagn Cytopathol 1999; 21: 328-330.
59. Carrara S, Cangi MG, Arcidiacono PG, et al. Mucin expression pattern in pancreatic diseases: Findings from EUS-guided fine-needle aspiration biopsies. Am J Gastroenterol 2011; 106: 1359-1363.
60. Maker AV, Katabi N, Gonen M, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 2011; 18: 199-206.
61. Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: A report of the PANDA study. Gastrointest Endosc 2009; 69: 1095-1102.
62. Shen J, Brugge WR, Dimaio CJ, Pitman MB,. Molecular analysis of pancreatic cyst fluid: A comparative analysis with current practice of diagnosis. Cancer 2009; 117: 217-227.
63. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 2011: 27; 21188-21193.
64. Kanda M, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013; 62: 1024-1033.
65. Tabareau-Delalande F, Collin C, Gomez-Brouchet A, et al. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: A retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Mod Pathol 2013; 26: 911-921.
66. Weinstein LS,. G(s)alpha mutations in fibrous dysplasia and McCune-Albright syndrome. J Bone Miner Res 2006; 21: P120-P124.
67. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3: 92ra66.
68. Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011; 1: 161.
69. Kim WY, Kaelin WG,. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.
70. van Asselt SJ, de Vries EG, van Dullemen HM, et al. Pancreatic cyst development: Insights from von Hippel-Lindau disease. Cilia 2013; 2: 3.
71. Ryland GL, Hunter SM, Doyle MA, et al. Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol 2013; 229: 469-476.
72. Macgregor-Das AM, Iacobuzio-Donahue CA,. Molecular pathways in pancreatic carcinogenesis. J Surg Oncol 2013; 107: 8-14.
73. Burford H, Baloch Z, Liu X, Jhala D, Siegal GP, Jhala N,. E-cadherin/beta-catenin and CD10: A limited immunohistochemical panel to distinguish pancreatic endocrine neoplasm from solid pseudopapillary neoplasm of the pancreas on endoscopic ultrasound-guided fine-needle aspirates of the pancreas. Am J Clin Pathol 2009; 132: 831-839.
74. Matthaei H, Wylie D, Lloyd MB, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res 2012; 18: 4713-4724.
75. Ryu JK, Matthaei H, dal Molin M, et al. Elevated microRNA miR-21 levels in pancreatic adenocarcinoma. Pancreatology 2011; 11: 343-350.
76. Thomas RM, Fleming JB,. Micro RNA dissects out dangerous pancreatic cysts from all the rest. Clin Cancer Res 18: 4482-4484.
77. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-2006.
78. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
79. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115-4121.
80. Burford H, Baloch Z, Liu X, Jhala D, Siegal GP, Jhala N,. E-cadherin/beta-catenin and CD10: A limited immunohistochemical panel to distinguish pancreatic endocrine neoplasm from solid pseudopapillary neoplasm of the pancreas on endoscopic ultrasound-guided fine-needle aspirates of the pancreas. Am J Clin Pathol 2009; 132: 831-839.
81. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-3868.
82. Agarwal B, Ludwig OJ, Collins BT, Cortese C,. Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol 2008; 6: 1425-1431.
83. Hruban RH, Pitman MB, Klimstra. AFIP Atlas of Tumor Pathology Series 4: Tumors of the Pancreas. Washington DC: The American Registry of Pathology; 2007: p 267-269.
84. Roth J, Klöppel G, Madsen OD, Storch MJ, Heitz PU,. Distribution patterns of proinsulin and insulin in human insulinomas: An immunohistochemical analysis in 76 tumors. Virchows Arch B Cell Pathol Incl Mol Pathol 1992; 63: 51-61.
85. Hamid QU, Hamid QA, Bishop AE, et al. Immunocytochemical characterization of 10 pancreatic tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers. Histopathology 1986; 10: 119-133.
86. Dayal Y, Oberg K, Perren A, Komminoth P,. Pancreatic endocrine tumours: Somatostatinoma. In:, DeLellis RA, Lloyd RV, Heitz PU, Eng C, editor. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. p 189-190.
87. Komminoth P, Perreu A, Oberg K, et al. Pancreatic endocrine tumours: Gastronoma. In:, DeLellis RA, Lloyd RV, Heitz PU, Eng C, editor. World Health Organization Classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. p 191-194.
88. Solcia E, Capella C, Riva C, Rindi G, Polak JM,. The morphology and neuroendocrine profile of pancreatic epithelial VIPomas and extrapancreatic VIP-producing neurogenic tumors. Ann NY Acad Sci 1988; 527: 508-517.
89. Faggiano A, Mansueto G, Ferolla P, et al. Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. J Endocrinol Invest 2008; 31: 216-223.
90. Scarpa A, Mantorani W, Capelli P,. Pancreatic endocrine tumors: Improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833.
91. Larghi A, Capurso G, Carnuccio A, et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained y EUS-guided Fine-needle tissue acquisition: A prospective study. Gastrointest Endosc 2012; 76: 570-577.
92. Kuerer H, Shim H, Pertsemlidis D, et al. Functioning pancreatic acinar cells carcinoma: Immunohistochemical and ultrastructural analyses. Am J Clin Oncol 1997; 20: 101-107.
93. Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinomas of the pancreas. A clinico-pathologic study of 28 cases. Am J Surg Pathol 1992; 16: 815-837.
94. Zamboni G, Terris B, Scarpa A, et al. Acinar cell cyst adenomas of the pancreas: A new entity? Am J Surg Path 2002; 26: 698-704.
95. Abraham SC, Wu TT, Hruban RH, et al. Genetic and immunohistochemical analysis of patriotic acinar cell carcinoma: Frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 2002; 60: 953-962.
96. Miettinen M, Partanen S, Fräki O, Kivilaakso E,. Papillary cystic tumor of the pancreas. An analysis of cellular differentiation by electron microscopy and immunohistochemistry. Am J Surg Pathol 1987; 11: 855-865.
97. Notohara K, Hamazaki S, Tsukayama C, et al. Solid-pseudopapillary tumor of the pancreas: Immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol 200; 24: 1361-1371.
98. Lüttges J, Schlehe B, Menke MA, Vogel I, Henne-Bruns D, Klöppel G,. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 1999; 85: 1703-1710.
99. Day JD, Digiuseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996; 27: 119-124.
100. Tanaka Y, Kato K, Notohara K, et al. Frequent beta-catenin mutation in cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res 2001; 61: 8401-8404.
101. Bouvet M, Staerkel GA, Spitz FR, et al. Primary pancreatic lymphoma. Surgery 1998; 123: 382-390.
102. Silverman JF, Holbrook CT, Pories WJ, Kodroff MB, Joshi VV,. Fine needle aspiration cytology of pancreatoblastoma with immunocytochemical and ultrastructural studies. Acta Cytol 1990; 34: 632-640.
103. Nishimata S, Kato K, Tanaka M, et al. Expression pattern of keratin subclasses in pancreatoblastoma with special emphasis on squamoid corpuscles. Pathol Int 2005; 55: 297-302.
104. Moskaluk CA, Hruban RH, Kern SE,. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997; 57: 2140-2143.
105. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE,. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-3573.
106. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996; 110: 227-231.
107. Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent K-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-956.
108. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS,. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 1998; 7: 515-521.
109. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T,. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 2000; 156: 2123-2133.
110. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res 1998; 58: 4740-4774.
111. Khalid A, Whitcomb DC,. The importance of autoimmune pancreatitis. Gastroenterology 2001; 121: 1518-1520.
112. Steele CW, Oien KA, McKay CJ, Jamieson NB,. Clinical potential of MicroRNAs in pancreatic ductal adenocarcinoma. Pancreas 2011; 40: 1165-1171.
113. du Rieu MC, Torrisani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010; 56: 603-612.
114. Nagao Y, Hisaoka M, Matsuyama A, et al. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma. Mod Pathol 2012; 25: 112-121.
115. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A,. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010; 10: 66-73.
116. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008; 54: 1716-1724.
117. Nodit L, McGrath KM, Zahid M, et al. Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome. Clin Gastroenterol Hepatol 2006; 4: 1474-1478.
118. Speel EJ, Scheidweiler AF, Zhao J, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: Gain of 9Q34 is an early event in insulinomas. Cancer Res 2001; 61: 5186-5192.
119. Barghorn A, Komminoth P, Bachmann D, et al. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol 2001; 194: 451-458.
120. Barghorn A, Speel EJ, Farspour B, et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol 2001; 158: 1903-1911.
121. Speel EJ, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparitive genomic hybridization. Am J Pathol 1999; 155: 1787-1794.
122. Stumpf E, Aalto Y, Hoog A, et al. Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer 2000:29: 83-87.
123. Hruban RH, Pitman MB, Klimstra DS,. AFIP Atlas of Tumor Pathology Series 4. Tumors of the Pancreas. Washington DC: The American Registry of Pathology: 2007: 271 p.
124. Huang SC, Ng KF, Yeh TS, Chang HC, Su CY, Chen TC,. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas. Ann Surg Oncol 2012; 19: S438-S446